CME: Advanced Practice Perspectives on CDK 4/6 Inhibitors: Paving the Way for HR+, HER2-Negative Early Breast Cancer

Advanced Practice Perspectives on CDK 4/6 Inhibitors: Paving the Way for HR+, HER2-Negative Early Breast Cancer

Host: Kristi K. Orbaugh, MSN, NP, AOCN®
Guest: Val R. Adams, PharmD, FCCP, BCOP, FHOPA
Guest: Theresa W. Gillespie, PhD, MA, RN, FAAN

Take Post-Test

If you’ve already completed the activity.

Overview
Endocrine therapy is currently the cornerstone of treatment for advanced hormone receptor–positive (HR+) breast cancer in both pre- and postmenopausal patients. However, not all advanced HR+ breast cancers respond to first-line endocrine therapy, and those that do respond eventually relapse. Agents that target critical pathways involved in resistance to endocrine therapy, such as cyclin-dependent kinase (CDK) 4/6 inhibitors, have been approved by the US Food & Drug Administration (FDA) for the treatment of HR+/human epidermal growth factor receptor 2–negative (HER2−) advanced/metastatic breast cancer. Now, CDK 4/6 inhibitors are being investigated for the treatment of early stage HR+, HER2- breast cancer.
This web-based, on-demand, activity will feature interprofessional perspectives and expert insights on the latest emerging evidence for CDK 4/6 inhibitors in the adjuvant setting for early breast cancer. The faculty panel will also provide their perspectives and best practice recommendations for improving adherence and side effect management. Case-based discussion will provide practical approaches for integrating CDK 4/6 inhibitors into real-world clinical practice for the treatment of early stage HR+, HER2- breast cancer.
Since the date of this activity’s recording, an exciting and practice changing advancement has occurred with the Food and Drug Administration’s (FDA) recent approval of abemaciclib with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score ≥20%, as determined by an FDA approved test. This marks the first advancement in adjuvant treatment of HR+ HER2- breast cancer in nearly two decades. This approval was based off of the landmark data from the MonarchE clinical trial which demonstrated a 37% reduction in the risk of recurrence in patients.
Learning Objectives
At the conclusion of this activity, participants should be better able to:
- Evaluate recent evidence supporting the use of CDK 4/6 inhibitors for the adjuvant treatment of HR+, HER2- early breast cancer to prevent early disease recurrences and reduce the risk of distant metastases.
- Assess the efficacy of CDK 4/6 inhibitors as adjuvant therapy in high-risk early breast cancer.
- Integrate strategies to promote and improve adherence in patients receiving oral CDK 4/6 inhibitors for the treatment of breast cancer.
- Develop a plan for assessing, monitoring, and managing side effects that may occur with oral CDK 4/6 inhibitors to prevent and reduce toxicities, treatment delays, and treatment discontinuation.
- Implement shared decision-making to foster co-creation of treatment plans, optimal adherence, and management of side effects with patients and their families.
Target Audience
This educational activity is intended for advanced practice clinicians, physician assistants, advanced practice nurses and pharmacists, oncology nurses, nurse navigators, and other healthcare professionals who are involved with the direct treatment and management of patients with HR+, HER2- breast cancer.
Faculty Disclosure
Disclosure of Conflict of Interest
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:
Kristi K. Orbaugh, MSN, NP, AOCN^®, reported a financial interest/relationship or affiliation in the form of Serve(d) as a speaker or a member of a speakers’ bureau for: Bristol-Myers Squibb Co; Pfizer, Inc; AstraZeneca Pharmaceuticals LP; Daiichi-Sankyo, Inc; Astellas Pharma US, Inc; Lilly USA; MorphoSys; Immunomedics, Inc; Gilead; and Coherus BioSciences.

Val R. Adams, PharmD, FCCP, BCOP, FHOPA, reported a financial interest/relationship or affiliation in the form of Research grant: Bristol-Myers Squibb Co. Consultant: Regeneron Pharmaceuticals, Inc.

Theresa W. Gillespie, PhD, MA, RN, FAAN, has no real or apparent conflicts of interest to report.
The planners, directors, managers, peer reviewers, and relevant staff reported the following financial relationships they have ineligible companies of any amount during the past 24 months: Linda Gracie-King, MS: Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; and. Adrienne N. Nedved, PharmD., MPA., BCOP hereby state that they do not have any financial relationships or relationships to products or devices with any ineligible company.
Accreditation and Credit Designation Statements
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Credit Designation for Physician Assistants
AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 07/26/2022 PAs should only claim credit commensurate with the extent of their participation.
Credit Designation for Pharmacists
This knowledge-based activity is approved for for 1.0 contact hour of continuing pharmacy education credit JA4008106-0000-21-054-H01-P.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Provider(s)/Educational Partner(s)
Provided by
Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
Terms of Use
Disclosure of Unlabeled Use
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation and Request for Credit:
To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.
There is no fee for this educational activity.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

- Sagar Lonial, MD
  Peer
- Noopur Raje, MD
  Peer
2
CME/CE
Novel Clinical Approaches in Multiple Myeloma: CAR T Cell Therapy
Novel Clinical Approaches in Multiple Myeloma: CAR T Cell Therapy
0.25 credits
Novel Clinical Approaches in Multiple Myeloma: CAR T Cell Therapy
0.25 credits
- Lyudmila Bazhenova, MD
  Peer
- Benjamin Levy, MD
  Peer
6
CME/CE
The Emerging Role of HER2 (ERBB2) Mutations in NSCLC
The Emerging Role of HER2 (ERBB2) Mutations in NSCLC
0.25 credits
The Emerging Role of HER2 (ERBB2) Mutations in NSCLC
0.25 credits
- Andrew M. Brunner, MD
  Peer
- Amy E. DeZern, MD, MHS
  Peer
3
CME/CE
A New Light in Higher-Risk MDS: Emerging Treatment Options
A New Light in Higher-Risk MDS: Emerging Treatment Options
0.25 credits
A New Light in Higher-Risk MDS: Emerging Treatment Options
0.25 credits
- Jacqueline Garcia, MD
  Peer
- David A. Sallman, MD
  Peer
2
CME/CE
Keeping Pace with Hematologic Malignancies: Understanding, Classifying, and Stratifying MDS
Keeping Pace with Hematologic Malignancies: Understanding, Classifying, and Stratifying MDS
0.25 credits
Keeping Pace with Hematologic Malignancies: Understanding, Classifying, and Str…
0.25 credits